In 2024, we strengthened and broadened our foundation for profitable growth through capacity expansions, the acquisition of Bormioli pharma and innovations.
We have ramped-up new production lines in the USA, Czech Republic and Republic of North Macedonia for drug delivery systems such as pens, auto-injectors and syringes. With the acquisition of Bormioli Pharma we have added an attractive, highly complementary product portfolio, welcomed 1,400 skilled employees into our group and laid the foundation for new, integrated high-value solutions.
We have formed new partnerships to leverage connected devices for remote therapeutic monitoring and medication adherence and added new systems and solutions dedicated to large-molecule biologics.
We have underlined the resilience of our business model in adverse market conditions.